Evofem Biosciences’ lead product candidate, Amphora® is an MPT – more specifically, a Multipurpose Vaginal pH Regulator (MVP-RTM) – that is being developed for the prevention of pregnancy and certain sexually transmitted infections (STIs), including chlamydia and gonorrhea.
Recharged from the holiday season, we are proud to share a few major highlights from our 2018 work as IMPT learning network manager – fostering connections between multidisciplinary partners; collecting, synthesizing, and disseminating MPT-relevant information; and accelerating action to advance progress in the field.
Every four minutes, three young women will become infected with HIV—that’s close to 900,000 new infections a year. While HIV prevention research and drug development have progressed rapidly, there is still work to be done. This World AIDS Day, we reflect on our work to advance MPTs by asking the IMPT Advisory Council for their perspective on the role of MPTs in the fight to end the HIV epidemic.
The IMPT is the first & only initiative dedicated to advancing the field of multipurpose prevention technologies (MPTs), products that combine HIV prevention, other STI prevention, and contraception.
IMPT Secretariat 1750 Howe Avenue, Suite 550 Sacramento, CA 95825 IMPT@cami-health.org
This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of Cooperative Agreement #AID-OAA-A-16-00045. The contents are the responsibility of the IMPT, CAMI Health, PHI, and its partners and do not necessarily reflect the views of USAID or the U.S. Government.